Unusual option trading volume observed in two cancer drug developers
SMMT Summit Therapeutics Inc
$10.67 -9.73%
View chart & analysis → - 1Summit Therapeutics Inc shares plunged 15% to a trading price of 12.02 dollars for SMMT.
- 2CG Oncology Inc rose 12.5% as the Phase 3 PIVOT-006 trial reduced recurrence risk by 68%.
- 3Option traders are maintaining a bearish outlook on both stocks.
So what's the key point?
Summit Therapeutics Inc shares fell significantly, while CG Oncology Inc shares rose. Investors are expecting the stock prices of both companies to go down.
Source Schaeffer's Research · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.